View Latest Medical and Pharma Bids and Tenders

Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Bosutinib, Atc L01Ea04 (Obg) For The Period 01.10.2024 - 30.09.2026

Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Allergen Extract From Exclusively Timothy Grass Pollen (Excl. Sut), Atc V01Aa02 For The Period 01.10.24-30.09.26

Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Bimekizumab, Atc L04Ac21 (Obo) For The Period 01.10.2024 - 30.09.2026

Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Dapagliflozin, Atc A10Bk01 (Obo) For The Period 01.10.2024 - 30.09.2026

Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Allergen Extract From Timothy Grass, Sweetgrass, Etc. (Excl. Sut), Atc V01Aa02 For The Period 01.10.24-30.09.26

Open House Drug Discount Agreements Treprostinil, Atc B01Ac21

Open House Drug Discount Agreements Telmisartan, Atc C09Ca07

Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For Medicinal Products Containing The Active Ingredient Raltegravir (Atc: J05Aj01).

Rfp-2024-2025-011-Drug Checking Services Kelowna

Metoprolol, Active Ingredient: Succinate Salt, Dosage: 25 Mg, Presentation: Controlled Release *